These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 29716939)

  • 21. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.
    Haling JR; Sudhamsu J; Yen I; Sideris S; Sandoval W; Phung W; Bravo BJ; Giannetti AM; Peck A; Masselot A; Morales T; Smith D; Brandhuber BJ; Hymowitz SG; Malek S
    Cancer Cell; 2014 Sep; 26(3):402-413. PubMed ID: 25155755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Examining Ligand-Based Stabilization of Proteins in Cells with MEK1 Kinase Inhibitors.
    Auld DS; Davis CA; Jimenez M; Knight S; Orme JP
    Assay Drug Dev Technol; 2015 Jun; 13(5):266-76. PubMed ID: 26107610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
    Mizukami T; Togashi Y; Sogabe S; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Nakajima TE; Boku N; Nishio K
    Int J Oncol; 2015 Aug; 47(2):499-505. PubMed ID: 26081723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MEK1/2 dual-specificity protein kinases: structure and regulation.
    Roskoski R
    Biochem Biophys Res Commun; 2012 Jan; 417(1):5-10. PubMed ID: 22177953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
    Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
    Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
    Van Dort ME; Galbán S; Wang H; Sebolt-Leopold J; Whitehead C; Hong H; Rehemtulla A; Ross BD
    Bioorg Med Chem; 2015 Apr; 23(7):1386-94. PubMed ID: 25766633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
    Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
    Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
    Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H
    Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Keeping Tumors Out of the MAPK Fitness Zone.
    Stern DF
    Cancer Discov; 2018 Jan; 8(1):20-23. PubMed ID: 29311225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
    Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
    Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors.
    Kiga M; Nakayama A; Shikata Y; Sasazawa Y; Murakami R; Nakanishi T; Tashiro E; Imoto M
    Sci Rep; 2015 Feb; 5():8155. PubMed ID: 25640451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome.
    Rodriguez-Viciana P; Rauen KA
    Methods Enzymol; 2008; 438():277-89. PubMed ID: 18413255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
    Nelson DS; van Halteren A; Quispel WT; van den Bos C; Bovée JV; Patel B; Badalian-Very G; van Hummelen P; Ducar M; Lin L; MacConaill LE; Egeler RM; Rollins BJ
    Genes Chromosomes Cancer; 2015 Jun; 54(6):361-8. PubMed ID: 25899310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors.
    Han S; Zhou V; Pan S; Liu Y; Hornsby M; McMullan D; Klock HE; Haugen J; Lesley SA; Gray N; Caldwell J; Gu XJ
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5467-73. PubMed ID: 16199156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B-Raf protein isoforms interact with and phosphorylate Mek-1 on serine residues 218 and 222.
    Papin C; Eychène A; Brunet A; Pagès G; Pouysségur J; Calothy G; Barnier JV
    Oncogene; 1995 Apr; 10(8):1647-51. PubMed ID: 7731720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in
    Wu PK; Hong SK; Park JI
    Mol Cell Biol; 2017 Sep; 37(18):. PubMed ID: 28674184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.